Company Overview
ENvue Medical, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry through its development of non-invasive biological response-activating devices designed for biofilm prevention, pain therapy, wound healing, and at-home administration without requiring medical professional assistance. The company's product portfolio includes specific technologies such as UroShield, which utilizes ultrasound-based mechanisms to deliver these therapeutic benefits. As a public entity, ENvue Medical, Inc. currently maintains a market capitalization of $2.64M and employs a workforce of 31 individuals to support its operations. The company reported a trailing twelve-month revenue of $2.69M, indicating a micro-cap status where the market valuation is significantly lower than the annual revenue generated. This disparity between the $2.64M market cap and the $2.69M revenue suggests that the stock trades at less than one dollar for every dollar of sales, reflecting a valuation where the market prices the entity primarily on its asset book value rather than earnings multiples or growth premiums.
Financial Health
The company reported a trailing twelve-month revenue of $2.69M, yet it posted a net income of -$4,583,000 and an EBITDA of -$8,806,000, revealing a substantial gap between top-line sales and bottom-line profitability. This significant divergence indicates a highly leveraged cost structure where operating expenses and interest obligations far exceed the gross profits generated from sales, resulting in a negative profit environment despite revenue growth. Notably, the company generated positive free cash flow of $662,000, which provides a crucial layer of financial flexibility that allows the firm to meet immediate obligations without relying solely on external financing. In terms of profitability margins, the gross margin stands at 30.0%, while the operating margin is -311.2% and the profit margin is -251.9%, demonstrating that the company loses money on every dollar of sales after covering all operating costs. The balance sheet shows a cash position of $6.95M against total debt of $3.17M, resulting in a debt-to-equity ratio of 7.46, which classifies the entity as highly leveraged despite holding sufficient cash to cover current debt obligations. The current ratio is 0.86, indicating that the company's current liabilities exceed its current assets, which presents a potential liquidity challenge in the short term. Furthermore, the return on equity is -30.5% and the return on assets is -20.0%, metrics that reveal that management is currently destroying shareholder value and failing to generate returns on the capital deployed in the business.
Valuation Assessment
The trailing P/E ratio is N/A and the forward P/E is N/A, a status that implies the company is not currently profitable and therefore cannot be valued using standard earnings-based multiples. Because earnings are negative, the difference between these metrics suggests that valuation is driven by asset liquidity and cash flow rather than expected future earnings per share in the near term. The price-to-book ratio is 0.06, which indicates that the market values the company at only 6% of its net asset book value, suggesting a deep discount or a lack of confidence in the asset base's recoverability. The price-to-sales ratio is 0.98 and the EV/EBITDA is 0.13, metrics that suggest the market is pricing the stock almost entirely on revenue generation while ignoring the significant negative earnings and EBITDA. The 52-week high is $162.50 and the 52-week low is $0.99, meaning the current trading price is positioned very close to the bottom of this extreme historical range. With a beta of 2.28, the stock exhibits high price volatility relative to the broader market, moving more than twice as much as the market index during periods of stability or stress.
Growth & Income
ENvue Medical, Inc. reported a revenue growth of 92.0% year-over-year, while earnings growth is N/A due to the company's continued net losses. The absence of positive earnings growth while revenue expands implies that the company is in a high-burn stage of development where top-line expansion has not yet translated into profitability. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Since there are no dividends to distribute, the company effectively reinvests its operations and available cash reserves into product development and market expansion rather than returning capital to shareholders. The overall growth and income profile reflects a high-risk, high-volatility micro-cap biotech device company that prioritizes aggressive revenue scaling and asset accumulation over immediate income generation or shareholder returns.